2 research outputs found
HemaMaxâ„¢, a Recombinant Human Interleukin-12, Is a Potent Mitigator of Acute Radiation Injury in Mice and Non-Human Primates
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medical need for effective treatments against acute radiation syndrome due to radiological terrorism or accident when administered at least 24 hours after radiation exposure. This study investigated pharmacokinetics, pharmacodynamics, and efficacy of m-HemaMax (recombinant murine IL-12), and HemaMax to increase survival after total body irradiation (TBI) in mice and rhesus monkeys, respectively, with no supportive care. In mice, m-HemaMax at an optimal 20 ng/mouse dose significantly increased percent survival and survival time when administered 24 hours after TBI between 8–9 Gy (p<0.05 Pearson's chi-square test). This survival benefit was accompanied by increases in plasma interferon-γ (IFN-γ) and erythropoietin levels, recovery of femoral bone hematopoiesis characterized with the presence of IL-12 receptor β2 subunit–expressing myeloid progenitors, megakaryocytes, and osteoblasts. Mitigation of jejunal radiation damage was also examined. At allometrically equivalent doses, HemaMax showed similar pharmacokinetics in rhesus monkeys compared to m-HemaMax in mice, but more robustly increased plasma IFN-γ levels. HemaMax also increased plasma erythropoietin, IL-15, IL-18, and neopterin levels. At non-human primate doses pharmacologically equivalent to murine doses, HemaMax (100 ng/Kg and 250 ng/Kg) administered at 24 hours after TBI (6.7 Gy/LD50/30) significantly increased percent survival of HemaMax groups compared to vehicle (p<0.05 Pearson's chi-square test). This survival benefit was accompanied by a significantly higher leukocyte (neutrophils and lymphocytes), thrombocyte, and reticulocyte counts during nadir (days 12–14) and significantly less weight loss at day 12 compared to vehicle. These findings indicate successful interspecies dose conversion and provide proof of concept that HemaMax increases survival in irradiated rhesus monkeys by promoting hematopoiesis and recovery of immune functions and possibly gastrointestinal functions, likely through a network of interactions involving dendritic cells, osteoblasts, and soluble factors such as IL-12, IFN-γ, and cytoprotectant erythropoietin
Identification of Contractile Vacuole Proteins in Trypanosoma cruzi
Contractile vacuole complexes are critical components of cell volume regulation
and have been shown to have other functional roles in several free-living
protists. However, very little is known about the functions of the contractile
vacuole complex of the parasite Trypanosoma cruzi, the
etiologic agent of Chagas disease, other than a role in osmoregulation.
Identification of the protein composition of these organelles is important for
understanding their physiological roles. We applied a combined proteomic and
bioinfomatic approach to identify proteins localized to the contractile vacuole.
Proteomic analysis of a T. cruzi fraction enriched for
contractile vacuoles and analyzed by one-dimensional gel electrophoresis and
LC-MS/MS resulted in the addition of 109 newly detected proteins to the group of
expressed proteins of epimastigotes. We also identified different peptides that
map to at least 39 members of the dispersed gene family 1 (DGF-1) providing
evidence that many members of this family are simultaneously expressed in
epimastigotes. Of the proteins present in the fraction we selected several
homologues with known localizations in contractile vacuoles of other organisms
and others that we expected to be present in these vacuoles on the basis of
their potential roles. We determined the localization of each by expression as
GFP-fusion proteins or with specific antibodies. Six of these putative proteins
(Rab11, Rab32, AP180, ATPase subunit B, VAMP1, and phosphate transporter)
predominantly localized to the vacuole bladder. TcSNARE2.1, TcSNARE2.2, and
calmodulin localized to the spongiome. Calmodulin was also cytosolic. Our
results demonstrate the utility of combining subcellular fractionation,
proteomic analysis, and bioinformatic approaches for localization of organellar
proteins that are difficult to detect with whole cell methodologies. The CV
localization of the proteins investigated revealed potential novel roles of
these organelles in phosphate metabolism and provided information on the
potential participation of adaptor protein complexes in their biogenesis